Premium
Letter to the Editor: Is Emricasan (IDN‐6556), an Oral Pan‐Caspase Inhibitor, Ready for Controlled Trials?
Author(s) -
Khurana Sandeep,
Khara Harshit S.
Publication year - 2019
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.30683
Subject(s) - medicine , portal venous pressure , portal hypertension , placebo , cardiology , gastroenterology , cirrhosis , pathology , alternative medicine